Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 247 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 11
Therapeutics Development 12
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 12
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 14
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 18
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 21
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 25
4SC AG 25
AbbVie Inc. 26
Astellas Pharma Inc. 27
Astex Pharmaceuticals, Inc. 28
AstraZeneca Plc 29
Boehringer Ingelheim GmbH 30
Bristol-Myers Squibb Company 31
Celgene Corporation 32
Emergent BioSolutions Inc. 33
F. Hoffmann-La Roche Ltd. 34
Genmab A/S 35
Gilead Sciences, Inc. 36
GlaxoSmithKline Plc 37
ImmunoGen, Inc. 38
Immunomedics, Inc. 39
Infinity Pharmaceuticals, Inc. 40
Innate Pharma SA 41
Juno Therapeutics Inc. 42
Karyopharm Therapeutics, Inc. 43
Les Laboratoires Servier SAS 44
LFB S.A. 45
MedImmune, LLC 46
Millennium Pharmaceuticals, Inc. 47
MorphoSys AG 48
Neopharm Ltd. 49
Novartis AG 50
Ono Pharmaceutical Co., Ltd. 51
Portola Pharmaceuticals, Inc. 52
Sanofi 53
TG Therapeutics, Inc. 54
Threshold Pharmaceuticals, Inc. 55
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 61
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
4SC-202 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ACP-196 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
afuresertib hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AGS-67E - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AT-7519 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AZD-6738 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BI-836826 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
BMS-986016 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
buparlisib hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
CC-122 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
cerdulatinib - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
duvelisib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
evofosfamide - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
FBTA-05 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
GS-9901 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
IMGN-529 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
IMMU-114 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
IPH-2201 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
JCAR-014 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
JCAR-015 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
MEDI-551 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MOR-208 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
moxetumomab pasudotox - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
nivolumab - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
obinutuzumab - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
ofatumumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Oshadi D + Oshadi R - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
otlertuzumab - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
pilaralisib - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
S-055746 - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
selinexor - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
spebrutinib besylate - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
TAK-659 - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
TGR-1202 - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
tisagenlecleucel-T - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
ublituximab - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
ublituximab [INN] + TGR-1202 - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
UC-961 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
ulocuplumab - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
urelumab - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
venetoclax - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 158
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 233
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 235
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 236
Featured News & Press Releases 236
May 31, 2015: TG Therapeutics Announces Presentations of Its Proprietary Combination of TG-1101 Plus TGR-1202 in Ongoing Phase I/Ib Dose Escalation Clinical Studies 236
May 21, 2015: Ofatumumab Data to Be Presented at 20th Congress of EHA 237
May 11, 2015: Abbvie To Present New Data From Studies Of Duvelisib Assets In Multiple Cancers At The 51st American Society Of Clinical Oncology Annual Meeting 239
May 06, 2015: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17P Deletion Genetic Mutation 240
Dec 05, 2014: Roche to present clinical data on obinutuzumab at ASH 240
Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting 241
Nov 06, 2014: Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting 242
Nov 06, 2014: Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL 243
Nov 06, 2014: Genmab Announces Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH) 244
Jul 31, 2014: GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL 245
Appendix 246
Methodology 246
Coverage 246
Secondary Research 246
Primary Research 246
Expert Panel Validation 246
Contact Us 246
Disclaimer 247

List of Tables

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2015 12
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Development by Companies, H1 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2015 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2015 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2015 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2015 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2015 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2015 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2015 32
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2015 33
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 34
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2015 35
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2015 36
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline Plc, H1 2015 37
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2015 38
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2015 39
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 40
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2015 41
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2015 42
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 43
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2015 44
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2015 45
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H1 2015 46
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 47
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2015 48
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Neopharm Ltd., H1 2015 49
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2015 50
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 51
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 52
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2015 53
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2015 54
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 55
Assessment by Monotherapy Products, H1 2015 56
Assessment by Combination Products, H1 2015 57
Number of Products by Stage and Target, H1 2015 59
Number of Products by Stage and Mechanism of Action, H1 2015 62
Number of Products by Stage and Route of Administration, H1 2015 64
Number of Products by Stage and Molecule Type, H1 2015 66
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2015 158
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2015 233
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2015 234
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2015 235